Information de reference pour ce titreAccession Number: | 01445404-201510000-00003.
|
Author: | Zhao, Huan 1; Zhang, Zhi-hui 1; Zhou, Bin 1; Xiao, Ting 2; Pan, Qin-jing 1; Guo, Hui-qin 1
|
Institution: | (1) Department of Pathology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China (2) State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China
|
Title: | |
Source: | Diagnostic Cytopathology. 43(10):786-790, October 2015.
|
Abstract: | Background: BRAF p.V600E mutation is the most common genetic alteration in papillary thyroid cancer (PTC) and has been used as a diagnostic and prognostic marker in PTC. The aim of this study was to investigate the utility of preoperative BRAF p.V600E mutation analysis as an adjunctive diagnostic and prognostic tool to routine fine-needle aspiration (FNA).
Methods: Specimens were collected from thyroid nodules by FNA. Cytology diagnosis and BRAF p.V600E testing were performed on these specimens. Molecular and cytological results were correlated with histology outcomes.
Results: A total of 195 patients with thyroid nodules were enrolled, including 25 benign lesions and 170 PTCs. BRAF p.V600E testing was successfully performed in all specimens. The combination of BRAF p.V600E testing and cytology improved the sensitivity of cytology from 70% to 85.3% (P = 0.001). This significant increase in sensitivity was due to the detection of PTC by BRAF p.V600E testing in the nodules with atypical or suspicious PTC cytology results. Patients with BRAF p.V600E-positive tumors were significantly older than those who did not harbor mutations (45.6 years vs. 39.8 years, P = 0.002). No correlations between BRAF p.V600E mutation and other clinical-pathology parameters were observed.
Conclusions: Detection of BRAF p.V600E mutation can be successfully carried out using residual liquid-based materials. It can be performed as a diagnostic tool to supplement traditional thyroid FNA, especially in cases with atypical or suspicious PTC. However, the role of BRAF p.V600E in guidance of the extent of thyroidectomy and nodal clearance requires further study. Diagn. Cytopathol. 2015;43:786-790. (C) 2015 Wiley Periodicals, Inc.
(C) 2015 John Wiley & Sons, Ltd
|
Author Keywords: | papillary thyroid carcinoma; BRAF p.V600E mutation; fine-needle aspiration; diagnosis; prognosis.
|
References: | 1. Ravetto C, Colombo L, Dottorini ME.. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: A retrospective study in 37,895 patients. Cancer. 2000; 90:357-363.
2. Werga P, Wallin G, Skoog L, Hamberger B.. Expanding role of fine-needle aspiration cytology in thyroid diagnosis and management. World J Surg. 2000; 24:907-912.
3. Frates MC, Doubilet PM, Gawande AA, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007; 111:508-516.
4. Fuhrer D, Mugge C, Paschke R.. Questionnaire on management of nodular thyroid disease (Annual Meeting of the Thyroid Section of the German Society of Endocrinology 2003). Exp Clin Endocrinol Diabetes. 2005; 113:152-159.
5. Filetti S, Durante C, Torlontano M.. Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab. 2006; 2:384-294.
6. Gharib H, Papini E.. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007; 36:707-735.
7. Mazeh H, Beglaibter N, Prus D, Ariel I, Freund HR.. Cytohistologic correlation of thyroid nodules. Am J Surg. 2007; 194:161-163.
8. Xing M.. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762.
9. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009; 94:1612-1617.
10. Melck AL, Yip L, Carty SE.. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010; 15:1285-1293.
11. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 2008; 93:3943-3949.
12. Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012; 97:4390-4398.
13. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAFV600E mutation in thyroid cancer. Ann Surg. 2007; 246:466-470.
14. Lupi C, Giannini R, Ugolini C, et al. Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92:4085-4090.
15. Prescott JD, Sadow PM, Hodin RA, et al. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012; 152:984-990.
16. Xing M, Clark D, Guan H, et al. BRAFV600E mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009; 27:2977-2982.
17. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013; 309:1493-1501.
18. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009; 146:1215-1223.
19. Dyhdalo K, MacNamara S, Brainard J, et al. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples. Cancer Cytopathol. 2014; 122:114-122.
20. Rossi ED, Martini M, Capodimonti S, et al. BRAF(V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol. 2013; 121:291-297.
21. Nikiforova MN, Nikiforov YE.. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009; 19:1351-1361.
22. Zatelli MC, Trasforini G, Leoni S, et al. Mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009; 161:467-473. BRAFV600E ;:-.
23. Marchetti I, Lessi F, Mazzanti CM, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAFV600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009; 19:837-842.
24. Xing M.. BRAFV600E mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12:245-262.
25. Yang J, Schnadig V, Logrono R, Wasserman PG.. Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. Cancer. 2007; 111:306-315.
26. Yang GC, Liebeskind D, Messina AV.. Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: Data from 1135 biopsies with a two- to six-year follow-up. Thyroid. 2001; 11:581-589.
27. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008; 36:425-437.
28. Li C, Lee KC, Schneider EB, Zeiger MA.. BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis. J Clin Endocrinol Metab. 2012; 97:4559-4570.
29. Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012; 203:436-441.
30. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAFV600E Mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer. 2007; 110:1218-1226.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 8755-1039
|
DOI Number: | https://dx.doi.org/10.1002/dc.23...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|